Hybio Pharmaceutical vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Hybio Pharmaceutical (300199.CS)

Q3 20267 Aug – 10 Sep 2026

▲4

Hybio advances GLP-1 pipeline and global reach as profits rise

Tirzepatide filing accepted, first in China Hybio's marketing application for tirzepatide injection was accepted by China's drug regulator, making it the first domestic company to file for this blockbuster diabetes and weight-loss drug. If approved, it opens a huge market and strengthens Hybio's GLP-1 leadership.
This is a major regulatory milestone that could significantly boost future revenue and market position.
Semaglutide partnership expands market reach Hybio signed a cooperation agreement for semaglutide injection in China, covering development, registration, production, and sales. This partnership should accelerate commercialization and broaden patient access, supporting revenue growth.
It directly adds a new commercial channel for a key GLP-1 product, enhancing Hybio's market presence.
Interim profit rises, cash flow strong Hybio reported a net profit of 237 million yuan for the first half of 2026, with operating cash inflow of 305 million yuan. Although gross margin dipped slightly, the profit and cash generation show a healthy core business.
Financial results confirm profitability and cash strength, underpinning investor confidence.
Liraglutide approved in Singapore, global push Hybio's liraglutide injection was approved by Singapore's health authority, marking another step in its international expansion. This follows U.S. approval and supports overseas sales growth, though actual sales timing and scale remain uncertain.
It demonstrates progress in global markets, a key growth driver for the company.

August 20267 Aug – 10 Sep 2026

▲4

Hybio advances GLP-1 pipeline and global reach as profits rise

Tirzepatide filing accepted, first in China Hybio's marketing application for tirzepatide injection was accepted by China's drug regulator, making it the first domestic company to file for this blockbuster diabetes and weight-loss drug. If approved, it opens a huge market and strengthens Hybio's GLP-1 leadership.
This is a major regulatory milestone that could significantly boost future revenue and market position.
Semaglutide partnership expands market reach Hybio signed a cooperation agreement for semaglutide injection in China, covering development, registration, production, and sales. This partnership should accelerate commercialization and broaden patient access, supporting revenue growth.
It directly adds a new commercial channel for a key GLP-1 product, enhancing Hybio's market presence.
Interim profit rises, cash flow strong Hybio reported a net profit of 237 million yuan for the first half of 2026, with operating cash inflow of 305 million yuan. Although gross margin dipped slightly, the profit and cash generation show a healthy core business.
Financial results confirm profitability and cash strength, underpinning investor confidence.
Liraglutide approved in Singapore, global push Hybio's liraglutide injection was approved by Singapore's health authority, marking another step in its international expansion. This follows U.S. approval and supports overseas sales growth, though actual sales timing and scale remain uncertain.
It demonstrates progress in global markets, a key growth driver for the company.

Latest7 Aug – 10 Sep 2026

▲4

Hybio advances GLP-1 pipeline and global reach as profits rise

Tirzepatide filing accepted, first in China Hybio's marketing application for tirzepatide injection was accepted by China's drug regulator, making it the first domestic company to file for this blockbuster diabetes and weight-loss drug. If approved, it opens a huge market and strengthens Hybio's GLP-1 leadership.
This is a major regulatory milestone that could significantly boost future revenue and market position.
Semaglutide partnership expands market reach Hybio signed a cooperation agreement for semaglutide injection in China, covering development, registration, production, and sales. This partnership should accelerate commercialization and broaden patient access, supporting revenue growth.
It directly adds a new commercial channel for a key GLP-1 product, enhancing Hybio's market presence.
Interim profit rises, cash flow strong Hybio reported a net profit of 237 million yuan for the first half of 2026, with operating cash inflow of 305 million yuan. Although gross margin dipped slightly, the profit and cash generation show a healthy core business.
Financial results confirm profitability and cash strength, underpinning investor confidence.
Liraglutide approved in Singapore, global push Hybio's liraglutide injection was approved by Singapore's health authority, marking another step in its international expansion. This follows U.S. approval and supports overseas sales growth, though actual sales timing and scale remain uncertain.
It demonstrates progress in global markets, a key growth driver for the company.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.